Background: Venous thromboembolism (VTE) complicates∼ 1.2 of every 1000 deliveries.
Despite these low absolute risks, pregnancy-associated VTE is a leading cause of maternal …

In July 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

PURPOSE To provide updated recommendations about prophylaxis and treatment of
venous thromboembolism (VTE) in patients with cancer. METHODS PubMed and the …

Background High-quality anticoagulation management is required to keep these narrow
therapeutic index medications as effective and safe as possible. This article focuses on the …

Purpose To provide recommendations about prophylaxis and treatment of venous
thromboembolism (VTE) in patients with cancer. Prophylaxis in the outpatient, inpatient, and …

This article describes the pharmacology of approved parenteral anticoagulants. These
include the indirect anticoagulants, unfractionated heparin (UFH), low-molecular-weight …

Heparin has been recognized as a valuable anticoagulant and antithrombotic for several
decades and is still widely used in clinical practice for a variety of indications. The …

This article discusses the prevention of venous thromboembolism (VTE) and is part of the
Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence …

Venous thromboembolism (VTE), which may manifest as pulmonary embolism (PE) or deep
vein thrombosis (DVT), is a serious and potentially fatal condition. Treatment and prevention …